The Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a corporate presentation that may be used by management in connection with investor conferences and meetings with investors.
|
Harrow, Inc. is a provider of ophthalmic disease management solutions in North America. The company markets a portfolio of FDA-approved branded ophthalmic pharmaceuticals in the U.S. and Canadian markets, focusing on conditions such as dry eye disease, age-related macular degeneration, cataracts, glaucoma, and ocular surface disorders. Key products include IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, NEVANAC, FRESHKOTE, MAXITROL, MAXIDEX, and IOPIDINE. Harrow also holds rights to biosimilars BYOOVIZ and OPUVIZ, as well as the corticosteroid BYQLOVI. The company maintains a research and development pipeline featuring MELT-300, a sublingual sedation formulation, and H-N08, an ophthalmic triamcinolone acetonide program. In February 2024, Harrow out-licensed Canadian rights for several products to Apotex Inc. The company partners with U.S. eyecare professionals to distribute its therapies. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - Specialty & Generic | Homepage harrow.com |
| Sector Healthcare | IR page harrow.com/investors | |
|
Tags
ophthalmic pharmaceuticals, dry eye disease, macular degeneration, biosimilars, ocular surface, procedural sedation, antibiotics, corticosteroids, antifungals, allergy relief, IHEEZO, VEVYE, TRIESENCE, BYOOVIZ, OPUVIZ, BYQLOVI, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, NEVANAC, FRESHKOTE, MAXITROL, MAXIDEX, IOPIDINE, MOXEZA, VEXOL, ECONOPRED, TOBRASONE, Cationorm PLUS, MELT-300, H-N08, CR-01, MELT-210, MKO Melt, Apotex Inc.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 1.156B |
| Market cap (USD) | $ 1.156B |
| P/E | -41.07 |
| PEG | — |
| P/BV | 39.59 |
| P/S | 3.81 |
| P/OCF | -60.98 |
| P/FCF | -56.78 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -8.4% |
| ROI | -1.7% |
| ROIC | 7.6% |
| Profit margin | -1.9% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 1,045.1% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 29 |
| Quality score | 5.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 272.303M | 199.614M | 130.193M | 88.595M | 72.476M | 48.871M | 51.165M | 41.372M | 26.774M | 19.942M | 9.716M | 1.66M | — | — | — | — | — | — |
| Net profit | -5.139M | -17.481M | -24.411M | -14.086M | -18.007M | -3.357M | 168K | 14.625M | -11.985M | -19.087M | -15.899M | -10.118M | -7.643M | -5.384M | -953.936K | -2.531M | — | — |
| Free cash flow | 42.977M | -23.797M | 2.38M | -892K | 3.296M | -1.962M | -518K | -1.081M | -9.575M | -18.102M | -12.138M | -7.229M | -4.459M | -1.916M | -291.16K | -2.298M | — | — |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 49 | 33.55 | 11.2 | 14.76 | 8.64 | 6.86 | 7.78 | 5.69 | — | — | — | — | — | — | — | — | — | — |
| Price performance 12m | 0.46 | 2 | -0.24 | 0.71 | 0.26 | -0.12 | 0.37 | — | — | — | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 2.92M | 1.53M | 1.91M | 2.01M | 2.66M | 4.47M | 6.25M | 36.3M | 116M | 111M |
| ↳ YoY growth | +247.7% | -47.7% | +25.2% | +5.0% | +32.5% | +67.9% | +39.8% | +480.3% | +220.9% | -4.7% |
| ↳ 5y CAGR | +89.9% | +25.9% | +8.9% | +32.5% | +80.1% | +125.2% | +110.8% | |||
| Borrowings, current (USD) | — | — | 720,000 | — | — | — | — | — | — | — |
| Lease liabilities (USD) | — | — | 2.62M | 7M | 7.26M | 6.3M | 8.06M | 7.33M | 9.29M | 8.79M |
| Cash and deposits (USD) | 8.85M | 4.02M | 6.84M | 4.95M | 4.1M | 42.2M | 96.3M | 74.1M | 47.2M | 72.9M |
| Intangible assets (USD) | 2.97M | 2.86M | 3.06M | 2.34M | 1.94M | 15.8M | 23.7M | 160M | 185M | 175M |
| Right-of-use assets (USD) | — | — | 2.11M | 6.56M | 6.8M | 5.94M | 7.51M | 6.79M | 8.55M | 7.78M |
| Net debt (borrowings + leases - cash) (USD) | — | — | 594,000 | — | — | — | — | — | — | — |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -11.2M | -8.8M | 687,000 | 950,000 | -1.1M | 5.08M | 1.71M | 3.84M | -22.2M | 43.9M |
| Purchases of property, plant and equipment (USD) | 6.89M | -772,000 | -1.77M | -1.47M | -862,000 | -1.79M | -2.6M | -1.46M | -1.6M | -887,000 |
| Purchases of intangible assets (USD) | -252,000 | -252,000 | -435,000 | -369,000 | -132,000 | -84,000 | -176,000 | -18,000 | -79,000 | — |
| Change in receivables (cash effect) (USD) | -2.08M | 1.39M | -384,000 | -95,000 | -866,000 | -1.83M | -1.86M | -30.3M | -80.2M | 5.01M |
| Change in inventories (cash effect) (USD) | -429,000 | -821,000 | 415,000 | -2.27M | -661,000 | -255,000 | -2.32M | -4.33M | 165,000 | -2.82M |
| Change in payables (cash effect) (USD) | 1.52M | 346,000 | 2.37M | 1.34M | -4.66M | 1.73M | 1.84M | 31.8M | 37.5M | -4.61M |
| Interest paid (cash effect) (USD) | -1.37M | -1.54M | -2.1M | -1.97M | -1.79M | -4.82M | -6.48M | -18.9M | -20.6M | -18.7M |
| Income taxes paid (cash effect) (USD) | -9,000 | -9,000 | -4,000 | -17,000 | -4,000 | -11,000 | -75,000 | — | -374,000 | -93,000 |
| Share-based compensation (USD) | 3.67M | 2.94M | 2.49M | 1.79M | 2.78M | 5.75M | 7.97M | 15.7M | 17.6M | 12.5M |
| Operating cash flow before change in receivables (USD) | -9.13M | -10.2M | 1.07M | 1.05M | -234,000 | 6.91M | 3.57M | 34.2M | 58M | 38.9M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -18.4M | -9.83M | -1.52M | -887,000 | -2.09M | 3.21M | -1.07M | 2.36M | -23.9M | 43M |
| Income detail | ||||||||||
| Research and development expense (USD) | 739,000 | 413,000 | 825,000 | 2.08M | 2.41M | 11.1M | 3.05M | 6.65M | 12.2M | 20.9M |
| ↳ 5y CAGR | +46.0% | -20.5% | -12.6% | +54.5% | +48.7% | +71.9% | +49.2% | +51.8% | +42.5% | +54.1% |
| Provision for credit losses (USD) | — | — | — | — | 213,000 | 35,000 | 81,000 | 332,000 | 120,000 | 468,000 |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | — | 9.1% | 1.0% | 1.5% | 1.6% | 0.2% | 0.4% |
| Reported | Mar 21, 2017 | Mar 8, 2018 | May 9, 2019 | Mar 13, 2020 | Mar 8, 2021 | Mar 10, 2022 | Mar 23, 2023 | Mar 19, 2024 | Mar 27, 2025 | Mar 2, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Third Quarter 2026 and Selected Highlights:
•Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year
•Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total revenue
•GAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, compared with a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025
•Adjusted EBITDA (a non-GAAP measure) of $21.2 million, compared with $(1.2) million in the second quarter of 2026 and $22.8 million in the third quarter of 2025
•Reaffirmed full-year 2026 revenue guidance of $350 million to $365 million; updated full-year 2026 Adjusted EBITDA guidance to more than $40 million, including fourth quarter Adjusted EBITDA of more than $33 million, compared with prior Adjusted EBITDA guidance of $80 million to $100 million
•Cash and cash equivalents of $75.3 million as of September 30, 2026
NASHVILLE, Tenn., November 9, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2026.
November 2, 2026
HarrowRx to Simplify Access to Harrow Products and Integrate Into the Eyecare Practice Workflow, Providing a Single Prescribing Destination Within Existing Electronic Medical Record (EMR) Systems
NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow’s entire portfolio directly within the electronic medical record (EMR) systems they already use. By connecting prescribing to product-specific fulfillment and patient-support services, HarrowRx is designed to make Harrow a more integrated part of a practice’s daily workflow.
Harrow believes HarrowRx is the first platform of its kind developed by a U.S. ophthalmic pharmaceutical company. Today, prescribing ophthalmic medicines can mean navigating multiple specialty pharmacies, fulfillment channels, and patient savings programs. With HarrowRx, which is powered by Harrow’s preferred pharmacy partner, PhilRx, eyecare professionals can prescribe all of Harrow’s branded products through a single destination in a connected EMR. The HarrowRx platform routes each prescription to the appropriate fulfillment channel and helps eligible patients access available support, creating a simple, reliable, and trusted experience for practices and a clearer path to treatment for patients.
“When I visit with customers, I consistently hear the same frustrations: figuring out which specialty pharmacy or hub handles each product, remembering to complete prior authorization forms, and making sure patients have access to every available manufacturer savings program,” said Mark L. Baum, Chief Executive Officer of Harrow. “We created HarrowRx to take that complexity off their plates and build upon the trust that our customers have in the Harrow brand. Harrow has always been willing to challenge the status quo to find better ways to serve physicians and patients. With our entire branded portfolio in one place within the EMR, we believe HarrowRx will become the go-to destination for prescribing Harrow medicines. As we continue to grow, we intend to add more features, services, and products, increasing the presence and value HarrowRx provides to our customers and their patients.”
How HarrowRx Works
HarrowRx brings prescribing, fulfillment, and patient support together behind one familiar access point. For eyecare professionals and their staff, that means fewer channels to navigate; for patients, it is intended to mean a more straightforward path to obtaining their prescribed medicine at the best price.
-
**One destination within the existing EMR.**HarrowRx is a licensed pharmacy registered on the Surescripts network, so it appears in the pharmacy finder of connected EMRs. Prescribers can locate HarrowRx by name, NCPDP ID (3694886), or NPI (1578473732) and select it without installing separate prescribing software or creating another login.
-
**Fulfillment coordinated behind the scenes.**HarrowRx supports prescription-benefit medicines, with PhilRx powering its pharmacy operations. Physician-administered, buy-and-bill products are routed through their respective distributors for support and fulfillment. Practices use one entry point while each medicine follows its appropriate fulfillment pathway.
-
**Access and affordability support for eligible patients.**HarrowRx connects applicable prescriptions with available benefits verification, savings, and patient-support programs, including completing insurance authorization forms. This reduces friction, including avoidable administrative steps for practices, ultimately helping patients navigate coverage and out-of-pocket costs.
To get started, prescribers can search for “HarrowRx” (or its NCPDP ID or NPI) in the pharmacy finder of a connected EMR, select it, and send the prescription as usual. Fulfillment options and patient-support programs vary by product and eligibility. If HarrowRx does not appear in their EMR’s pharmacy finder, prescribers can also send prescriptions to HarrowRx by phone at 855-977-0975 or by fax at 888-975-0603. For questions and additional support, practices can contact clinical support at 855-977-0975 or their Harrow account representative.
“In a busy ophthalmology practice, the work doesn’t end when a physician makes a treatment decision,” said Baylee Douglas, Certified Ophthalmic Technician at Duke University Eye Center. “Getting a prescription to the right pharmacy and helping patients navigate the steps that follow can involve a great deal of coordination. Because Harrow offers several products prescribed in our practice, having a single prescribing destination within the EMR we already use could help simplify that process. I work with medication access and prescription coordination every day, and I see firsthand how complicated these workflows can become. Reducing unnecessary steps for physicians and staff while making it easier for patients to access their prescribed treatment is a meaningful step forward.”
“For optometrists treating chronic conditions such as dry eye, prescribing is only one part of helping patients begin therapy,” said Paul Karpecki, OD, Director of Cornea and External Disease at Kentucky Eye Institute. “HarrowRx offers a straightforward way to prescribe Harrow medicines and connect eligible patients with available affordability support. This kind of common-sense innovation is what I have come to expect from Harrow and demonstrates how they understand the way my practice actually works.”
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of any acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Investor & Media Contact: Mike Biega Vice President of Investor Relations and Communications [email protected] 617-913-8890

Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Sep 29, 2023 | Renamed | HARROW HEALTH, INC. → HARROW, INC. |
| Dec 31, 2018 | Renamed | IMPRIMIS PHARMACEUTICALS, INC. → HARROW HEALTH, INC. |
| Mar 27, 2012 | Renamed | TRANSDEL PHARMACEUTICALS INC → IMPRIMIS PHARMACEUTICALS, INC. |
| Sep 13, 2007 | Renamed | Bywater Resources, Inc → TRANSDEL PHARMACEUTICALS INC |
ETFs Holding Harrow, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| PSC | 0.10% | 53,287 | $ 2.263M | Jun 30, 2026 |
| AVSC | 0.03% | 36,610 | $ 1.065M | Nov 16, 2026 |
| DFAS | 0.02% | 220,467 | $ 6.239M | Nov 12, 2026 |
| MSSM | 0.01% | 1,148 | $ 42.373K | Aug 31, 2026 |
| DXUV | 0.01% | 11,171 | $ 316.139K | Nov 12, 2026 |
| DFAC | 0.00% | 99,467 | $ 2.815M | Nov 12, 2026 |
| DCOR | 0.00% | 27,595 | $ 780.939K | Nov 12, 2026 |
| DFAU | 0.00% | 5,911 | $ 167.281K | Nov 12, 2026 |
| DFUS | 0.00% | 9,698 | $ 274.453K | Nov 12, 2026 |
| EBI | 0.00% | 231 | $ 8,526.21 | Aug 31, 2026 |
| AVUS | 0.00% | 16,788 | $ 488.363K | Nov 16, 2026 |


